CD16(+) MONOCYTES IN PATIENTS WITH CANCER - SPONTANEOUS ELEVATION AND PHARMACOLOGICAL INDUCTION BY RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR
CD16(+) MONOCYTES IN PATIENTS WITH CANCER - SPONTANEOUS ELEVATION AND PHARMACOLOGICAL INDUCTION BY RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR
复制标题
DOI：
10.1182/blood.v85.10.2910.bloodjournal85102910
复制
发表时间：
1995-05-15
期刊：
影响因子：
20.3
通讯作者：
MUNN, DH
中科院分区：
文献类型：
--
作者：
SALEH, MN;GOLDMAN, SJ;MUNN, DH
最近据报道，在细菌性脓毒症患者中，一小部分表达成熟相关 CD16 抗原的循环单核细胞的表达水平升高。我们现在表明，这种新型 CD16(+) 单核细胞群在癌症患者中也会自发扩增。我们研究了参加重组人巨噬细胞集落刺激因子 (rhMCSF) 加单克隆抗体 D612 临床试验的 14 名转移性胃肠癌患者。我们发现，在任何细胞因子治疗之前，与正常受试者和单核细胞计数升高但无恶性肿瘤的患者相比，14 名患者中有 12 名的 CD16(+) 单核细胞百分比和绝对数量均表现出显着升高。 CD16(+) 单核细胞占癌症患者总单核细胞的 46% +/- 22%，而对照组为 5% +/- 3%（P
The small subset of circulating monocytes that express the maturation-associated CD16 antigen has recently been reported to be elevated in patients with bacterial sepsis. We now show that this novel CD16(+) monocyte population is also spontaneously expanded in patients with cancer. We studied 14 patients with metastatic gastrointestinal carcinoma enrolled in a clinical trial of recombinant human macrophage colony-stimulating factor (rhMCSF) plus monoclonal antibody D612. We found that before any cytokine treatment, 12 of 14 patients constitutively displayed significant elevations in both the percentage and the absolute number of CD16(+) monocytes, as compared with both normal subjects and ill patients with elevated monocyte counts but without malignancy. CD16(+) monocytes accounted for 46% +/- 22% of total monocytes in the patients with cancer versus 5% +/- 3% for controls (P